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Abstract Our aim was to systematically identify and
compare how generic medications, as defined by the US
Food and Drug Administration (FDA), World Health Or-
ganization (WHO), and European Medicines Agency
(EMA), are classified and defined by regulatory agencies
around the world. We focused on emerging markets and
selected the most populated countries in each of the WHO
regions: Africa, the Americas, Eastern Mediterranean,
Europe, Southeast Asia, and Western Pacific. A structured
review of published literature was performed through De-
cember 2013. Direct information from regulatory agencies
and Ministries of Health for each country was extracted.
Additionally, key informant interviews were performed for
validation. Of the 21 countries selected, approximately half
provided an official country-level definition for generic
pharmaceuticals. The others did not have any definition or
referred to the WHO. Only two-thirds of the countries had
specific requirements for generic pharmaceuticals, often
associated with clinical interchangeability. Most countries
with requirements mention bioequivalence, but few re-
quired bioavailability studies explicitly. Over 30 % of the
countries had other terms associated with generics in their
definitions and processes. In countries with generic drug
policies, there is reference to patent and/or data protection
during the drug registration process. Several countries do
not mention good manufacturing practices as part of the
evaluation process. Countries in Africa and Eastern
Mediterranean regions appear to have a less developed
regulatory framework. In summary, there is significant
variability in the definition and classification of generic
drugs in emerging markets. Standardization of the defini-
tions is necessary to make international comparisons
viable.
Key Points for Decision Makers
The classification and definition of generic
pharmaceutical products is different across the
world.
The impact of these differences in the definition and
requirements of generic pharmaceutical products is
unknown.
The differences in the definition and classification of
generic pharmaceutical products must be taken into
consideration when performing international
comparisons, including the impact of drug policies.
1 Background
The World Health Organization (WHO), during the World
Health Assembly in 1975, published a resolution to
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develop means to assist Member States in formulating
national drug policies [1]. Since then, and following the
recommendations of the WHO, many countries have de-
veloped their own national drug policies [2]. The frame-
work of these recommendations is often considered to be
built around improving access to ‘‘essential drugs’’ that in
most cases mirror the Essential Medicines List from the
WHO [3], currently in its 18th edition [4]. According to the
WHO, this list includes the most efficacious, safe and cost-
effective medicines for priority conditions. Most of the
drugs included are off-patent and available as generic
products, which are often offered at lower prices than the
innovator branded product, potentially reducing costs for
patients and the healthcare system [5]. The use of generic
pharmaceutical products is then promoted, in order to re-
duce costs and increase access to healthcare [6]. But, de-
spite highlighting the need for rigorous quality and safety
assessments for pharmaceutical products in order to
achieve these goals, the quality of pharmaceutical products
available in the market in many developing countries
varies, in part because of the lack of clear and specific
requirements for generic pharmaceutical products [7, 8].
Currently, the use of generic pharmaceutical products
represents over half of the total volume of pharmaceutical
products used worldwide but only 18 % of the total value
of the pharmaceutical market [9]. These proportions vary
by region and country, but the consumption of generic
pharmaceutical products is consistently higher than that of
innovators in most countries, being one of the most used
healthcare technologies around the world [10]. The WHO
defines a generic product as ‘‘a pharmaceutical product,
usually intended to be interchangeable with an innovator
product, that is manufactured without a license from the
innovator company and marketed after the expiry date of
the patent or other exclusive rights’’ [11]. In the USA, the
Food and Drug Administration (FDA) has stated that, ‘‘A
generic drug is identical—or bioequivalent—to a brand
name drug in dosage form, safety, strength, route of ad-
ministration, quality, performance characteristics and in-
tended use’’ [12]. Finally, the European Medicines Agency
(EMA), the main regulatory body for pharmaceutical
products in the EU, defines a generic medicinal product as
a ‘‘product which has the same qualitative and quantitative
composition in active substances and the same pharma-
ceutical form as the reference medicinal product, and
whose bioequivalence with the reference medicinal product
has been demonstrated by appropriate bioavailability
studies. (Reg. 726/2004, Art 10, 2b)’’ [13].
These definitions are critical when regulatory agencies
in each country determine the requirements and standards
that pharmaceutical products must follow in order to ob-
tain approval and reach the market. Minor differences in
wording may have a great impact on how these products
are assessed and the standards that must be followed. For
example, using words such as ‘‘interchangeable’’, ‘‘iden-
tical’’ or ‘‘bioequivalent’’, which are used by the WHO,
FDA and EMA, respectively, have important connotations
with regard to determining the evidence required from a
manufacturer of generic products in order for them to
obtain approval by regulatory agencies and reach the
market in specific countries. The concepts of bioe-
quivalence and interchangeability are of particular im-
portance in these definitions. In theory, a generic drug is
considered interchangeable with an innovator or a refer-
ence pharmaceutical product when there is evidence
demonstrating that it can be as effective and safe for pa-
tients in the specific indication. That evidence is often but
not always obtained through bioavailability and bioe-
quivalence studies comparing the generic to the innovator
as the reference product.
If the definition of generic drug in the regulation of
pharmaceutical products in a specific country involves the
terms ‘‘interchangeable’’ or ‘‘bioequivalence’’, as previ-
ously described, it will generally increase the supporting
evidence required from manufacturers when submitting a
new generic application. On the other hand, the absence of
these terms from the definition may be interpreted as if that
evidence is not required or is required only for specific
high-risk drugs, allowing for products without demon-
strated ‘‘interchangeability’’ or ‘‘bioequivalence’’ to be
approved and brought onto the market.
Reductions in national drug spending of more than 40 %
have been estimated if generic penetration reached a
maximum in each country [14]. In the USA, generic
medications cost less than one-third of their branded
counterparts [15]. The reduced price allows providers to
treat more patients effectively with the same amount of
overall dollars. However, these concepts are conditional on
bioequivalent generics being substituted. While numerous
cost-savings analyses have been conducted suggesting
significant reductions in drug expenditure, these analyses
have been conducted in settings where bioequivalent
generics were regulated and prevalent. In developing
countries, we are currently limited to conjecturing possible
cost savings from appropriate generic substitution. This
manuscript sheds light on the likelihood that a generic
medication is a clinically appropriate substitute.
The definition and classification of generic pharmaceu-
tical products are not the same across the world. Our aim is
to describe and compare the differences in the classification
and definitions of generic pharmaceutical products in the
largest developing countries, where more than 80 % of the
world’s population is currently living and receiving
healthcare [16].
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2 Methods
Using the six WHO geographic regions (the Americas,
Africa, Southeast Asia, Europe, Eastern Mediterranean,
Western Pacific), we identified the developing countrieswith
the largest population in each region and selected a total of 21
countries for the analysis: Brazil, Mexico, Colombia, Nige-
ria, Ethiopia, Democratic Republic of Congo, India, In-
donesia, Bangladesh, Russia, Turkey, Ukraine, Pakistan,
Egypt, Iran, Sudan, Saudi Arabia, Afghanistan, Yemen,
China and Korea (Table 1). Additional economic informa-
tion about gross domestic product (GDP) per capita and the
percentage of GDP devoted to healthcare expenditures was
also extracted as a proxy for the weight given to healthcare
investment as public policy (Fig. 1).
An individual country profile was created using infor-
mation from published literature, available through
PubMed and Google Scholar, and official government
sources available online. Websites from the Ministry of
Health, regulatory agencies or other government sites were
identified for each of the selected countries and reviewed to
extract the most recent and relevant information about the
definition and classification of pharmaceutical products,
focusing on generic pharmaceutical products. Finally, key
informant interviews were performed with experts in
regulation of pharmaceutical products for specific countries
where information was limited or where additional con-
firmation was required to complete the information.
The information was summarized and standardized for
comparison across countries, focusing on the main com-
ponents of the definitions and classification of pharma-
ceutical products (until December 2013).
3 Results
The information available about the regulation and
definition of generic pharmaceutical products in each of the
21 countries included in the analysis was very heteroge-
neous, with different levels of access to the information.
Some countries had information that was easy to access
and review about the regulation and definition of pharma-
ceutical products, but many others did not. Of the 21
countries selected, we were able to identify specific in-
formation about the definition of generic pharmaceutical
products from government or other official sources from
only 13 countries (62 %). For five countries (24 %) we
located generic medication related-details, but not from
‘‘official’’ government sources. For Afghanistan, the in-
formation was under review by the WHO. For Yemen and
Colombia, we could not identify specific definitions for
generic pharmaceutical products via government or other
official sources1 (Table 2).
Interestingly enough, in 20 of the 21 countries selected,
we were able to identify references to country-specific
pharmaceutical drug policies, mostly in concordance with
the initial resolution of the WHO in the late 1970s and its
updates since then. Consistently, these same countries have
references to most of the components of the pharmaceutical
policy delineated by the WHO, which includes selection of
essential medicines, affordability, drug financing, supply
system, drug regulation, research, and monitoring and
evaluation. The only country without an explicit reference
to a country-specific pharmaceutical drug policy was
Korea, which, in fact, is notably absent from the WHO’s
list of countries with essential medicines lists [15]. Nev-
ertheless, Korea’s regulatory policies mention other im-
portant components of the WHO pharmaceutical policy
framework, focusing on drug financing, drug regulation,
and monitoring and evaluation.
Table 1 Characteristics of countries selected by WHO region
Country Population Health
expenditures
as % of GDP
China 1,302,350,455 4.0
India 1,139,737,707 4.0
Indonesia 226,999,190 2.0
Brazil 185,416,160 7.0
Pakistan 158,874,699 2.0
Russian Federation 143,593,754 5.0
Nigeria 140,307,544 4.0
Bangladesh 139,913,660 3.0
Mexico 106,602,288 5.0
Egypt, Arab Rep. 74,266,212 5.0
Ethiopia 74,253,849 4.0
Iran, Islamic Rep. 69,724,855 5.0
Turkey 68,174,186 5.0
Congo, Dem. Rep. 57,535,109 4.0
Korea, Rep. 48,230,364 5.0
Ukraine 47,264,656 6.0
Colombia 43,038,783 6.0
Sudan 30,655,713 3.0
Afghanistan 30,005,286 7.0
Saudi Arabia 23,864,238 3.0
Yemen, Rep. 20,741,624 4.0
Total population
selected countries
4,131,550,331 4.4
Dem. Democratic, GDP gross domestic product, Rep. Republic, WHO
World Health Organization
1 However, in the case of Colombia, the regulation makes explicit
reference to the notion of ‘‘bioavailability,’’ suggesting an explicit
decision to avoid distinctions between originator and generic drugs
(Decreto 677 de 1995).
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In almost a third of the countries, where information was
available, there are other terms associated with generic
products, making market differentiation difficult. Those
terms are sometimes based on whether or not the generic
product is branded, or if it has been labeled as inter-
changeable, or as a similar product. Usually, ‘‘similar’’
pharmaceutical products, sometimes called ‘‘copies’’, are
pharmaceutical products with the same International Non-
proprietary Name (INN) as the reference generic pharma-
ceutical product, but with limited or no evidence of
bioequivalence and bioavailability. Most of the countries
selected in this study (16 of 21), mentioned requiring some
level of bioequivalence testing, mostly in vitro, to provide a
specific label for generic pharmaceutical products.
A requirement to have the innovator pharmaceutical
product off-patent in order to have a generic approved
seems to be consistently reported across all countries that
are in line with the Intellectual Property Rights Related to
Trade (TRIPS) agreement, which requires all World Trade
Organization members to adhere to it [16]. Nevertheless,
the fact that many pharmaceutical companies decide not to
file patents in every country allows for generic pharma-
ceutical products to emerge in those countries despite the
product being under patent in other countries.
Another important consideration for the quality of
generic pharmaceutical products is the requirement of good
manufacturing practices (GMP); except for some countries
in the Middle East, all countries included in the analysis
had some documentation referring to GMP as part of the
local pharmaceutical policy. Most countries did not
explicitly mention tax exemptions or incentives for pro-
duction or importation of generic pharmaceutical products.
In the same token, most countries did not offer specific
market protection for generic products.
4 Discussion
Using selected developing countries from every WHO re-
gion, on the basis of population size, we examined the
current pharmaceutical policies and regulation focusing on
the definition and requirements for generic pharmaceutical
products. We found important differences between coun-
tries in terms of the definitions used for pharmaceutical
generic products and other terms or definitions associated
with generic products, such as similars, copies, branded
generic products, etc. These differences and inconsisten-
cies bring important challenges for international compar-
isons that must be addressed and recognized. The
availability of generic products with different standards in
each country limits the generalizability of the assessment
of country-specific policies, as well as the pooling of in-
formation from multiple countries to assess the impact of
generic pharmaceutical products on general or specific
health outcomes. Previous research has recognized these
differences in specific countries or regions [17, 18]. In
2011, Vacca et al. [19] published a report comparing the
pharmaceutical regulation regarding generic products in 14
countries in the Americas, showing three levels of policy
for generic pharmaceutical products: (1) countries with
(% GDP)
Fig. 1 Population and
healthcare expenditure as
percentage of GDP. GDP gross
domestic product
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minimal or no specific regulation; (2) countries with
regulation, but without restrictions for substitutions be-
tween different types of generics; and (3) countries with
specific regulation and restrictions if therapeutic equiva-
lence is not demonstrated [20]. If we applied a similar
framework to our analysis, most of the countries in our
sample would be grouped in levels 2 and 3. Vacca et al.
placed most of the countries in level 1, minimal or no
regulation. However, the countries included in their se-
lection were largely countries with less developed econo-
mies and relatively smaller populations than those we
included for review here. Our analysis sought to capture a
wider representation of countries in terms of population
size and economic scale. This likely explains the differ-
ences in relative proportions found in our study compared
with their work.
In 2013, Nguyen et al. [21] performed a summary
description of generic medicines policies in Asia Pacific.
The authors, who retrieve the information from a Work-
shop in the region performed in 2012, said that many
countries in this region did not have a generic medicines
policy within their national medicines policy, and that
only a few countries had comprehensively implemented
generic medicines policies with strong regulatory re-
quirements. The participants on the workshop identified
barriers to successful implementation of generic medici-
nes policies, including mistrust of the quality of generic
pharmaceutical products and the lack of inspectors or
regulatory bodies to assess them properly. Finally, it was
reported that the financial benefit from generic substitu-
tion had not been measured or was unclear in many
countries, despite clear incentives to implement it. Our
results are in line with the initial points made by the
authors. The local perspectives about generic policies
were out of our scope since we focused on information
published or available from official sources and not from
surveys or workshops.
Vogler [22], in 2012, performed an analysis on the im-
pact of pharmaceutical pricing and reimbursement policies
on generics uptake in 29 European countries. Although the
focus of the paper was on reimbursement of generics, the
author highlights some differences between countries in the
definition and use of generics in these countries.
Clearly, as expressed in the previous reports, one of the
main challenges for this type of international analysis is the
heterogeneity in the availability and structure of the in-
formation about pharmaceutical policies and regulations in
each country. Continuous changes in the healthcare system
and changes in regulatory processes and policies for the
assessment and coverage of health technologies, including
pharmaceutical products, in each country are also difficult
to follow closely and understand regarding the potential
impact across regions.
On the extreme end of medication production is drug
counterfeiting: the creation of medications that claim to
have an active ingredient when they are devoid of the
chemical. As more of the world’s medicine production has
shifted to the developing world, recent studies have at-
tempted to investigate this phenomenon. The WHO
speculated that up to 30 % of the total drug market in
developing countries without regulatory oversight may be
counterfeit. However, the WHO used a broad definition of
counterfeit drugs that included mislabeled or fraudulently
labeled drugs even if they contained the correct active in-
gredients [22]. The challenge is not a simple matter of
reducing the supply of counterfeit drugs; it will also entail
reducing consumer demand. In some developing countries,
patients or their caregivers actively seek cheap medica-
tions, supplied without a preceding prescription, from non-
licensed peddlers. These demand-side forces have incen-
tivized a counterfeit medication para-economy. The WHO
has recommended that community-based organizations
disseminate information to improve surveillance of drug
counterfeiters and for governmental and non-governmental
education campaigns to reduce consumption of counterfeit
medications. This again potentiates the need for clear de-
velopment of a patient-centered definition of a generic
medication.
5 Conclusions
In summary, the significant variability in the definition and
classification of generic pharmaceutical products in
emerging and developing countries limits the opportunity
to compare and analyze the impact of policies and pro-
grams that incentivize their use. Standardization of the
definitions is necessary to make international comparisons
viable. Global efforts are underway to harmonize the
definition and regulation of generic medicines. However,
these attempts will likely need to be accelerated given the
increased availability of medications that are past patent
expiry.
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